メニュー
Professional & Student Poster Presentations
Student
- M-01: Impact on the Cost and Safety of Generic Sildenafil Citrate in the USA
- M-03: Assessment of the United States REMS Program Requirements for NDAs and BLAs
- M-04: Exploring and Addressing Gaps in GCP Training: Practical Approaches to Monitoring
- M-05: Effect of Transplant Status in CD19-Targeted CAR T-Cell Therapy: A Systematic Review and Meta-Analysis
- M-06: Drug-Eluting Bead (DEB) Versus Conventional Transarterial Chemoembolization for Intermediate Stage Hepatobiliary Malignancies
- M-07: Impact of Sofosbuvir/Velpatasvir/Voxilaprevir Intervention on Recent Remission Rates of Direct Acting Antivirals.
- M-08: Utilization, Assessment, and Return-on-Investment of Drug Information (DI) Websites in the US Pharmaceutical Industry
- M-09: The Impact of Direct-to-Consumer Advertisements on Patient Decision-Making in an Urban Environment
- M-10: Pharmacogenomics in Opioid Use Disorder Managment
- M-11: Contemporary Trends and Issues in Medication Non-Adherence: A Systematic Review
- M-12: Completing Patient-Reported Outcome Measures Electronically: A Review of the Literature on Subject Burden in Clinical Trials
- M-13: Synthesis of Tetrahydrobenzonaphthyridines as a Novel Series of Antimalarial Compounds
- M-16: Inhibition of Interferon-Gamma or Palmitate-Induced Inflammation in Type 2 Diabetes by Prebiotic Dietary Metabolites
- M-17: Awareness of HIV and Transmission Routes, Access to Health Knowledge in Western China: A Cross-Sectional Questionnaire Study
- M-18: Analysis of Drug Labeling for Information Specific to Geriatric Populations
- M-19: Disparities Between FDA and EMA Regulatory Review Processes
- M-20: Analysis of Indian National Guidelines for Stem Cell Research: A Path to Good Clinical Practice and Patient Care.
- M-21: Thirty Years Later: A Look Back at the Impact of AIDS Activism on Drug Development
- M-22: Quality Challenges in Cellular Therapy: An Examination of Regulatory Compliance in Manufacturing Institutions
- M-23: Analysis of FDA Warning Letters (2013-2017) of Active Pharmaceutical Ingredients (APIs) Made in China and India
- M-24: Factors Associated with Treatment Outcomes for Patients with Extremely Drug Resistant TB: A Random Survival Forest Approach
- M-25: Reliability and Validity of Outcomes Data Using Statistical Methods for Wearable Medical Devices: A Systematic Review
- M-26: Like We Have a Choice: A Qualitative Study of Patients’ Views on Epoietin Biosimilars for Anemia of Chronic Kidney Disease
- M-27: Effect of Drug Shortages on Pricing of Competitor Products
Professional
- T-01: A Novel Approach to Standardizing Data and Detecting Duplicates Across Adverse Events Data Sources Using Machine Learning
- T-02: Assessing the Value of a Comprehensive, Global Web-Based Pharmacovigilance Educational Platform
- T-04: Understanding Pharmacovigilance Challenges and Complexities in Medical Devices: US and EU Perspective
- T-05: Aggregate Reports: Quality Control, Feedback and Continuous Improvement
- T-06: Investigating the Utility of Minimally Invasive Sample Collection Technologies and Their Role in Clinical Trials
- T-07: Incremental Implementation of Risk-Based Monitoring in a Resource-Constrained
- T-08: Analyzing Real-World Data To Target Hard-to-Identify Patient Populations for Clinical Trials: A Case Study in Blood Cancers
- T-09: Use of Real-World Data to Optimize Identification of Systemic Lupus Erythematosus (SLE) Patients for Clinical Trial Enrolment
- T-10: Real-World Data Meets Real World Evidence in Patient Recruitment and Engagement
- T-11: Assessing Patient Availability and Patient Burden: Where Trials Go Wrong Today and How They Can Improve Tomorrow
- T-12: Risk-Adapted Monitoring Approach in Academic Medical Center: What we Learned From Multi-Center Investigator Sponsored Trials
- T-13: Protocol Deviation Reporting and Tracking Without a Deviations Case Report Form
- T-14: Automate the Process to Ensure the Compliance with FDA Business Rules in SDTM Programming for FDA Submission
- T-15: Mapping Items in the Case Report Form to CDISC SDTM Standards Using Pre-Map Function in the Electronic Data Capture System
- T-16: The Non-Traditional Role: Pharmacists in Medical Information
- T-17: Making Clinical Trials More Patient-Centered: Results of a Key Stakeholder Engagement Workshop
- T-18: Understanding the Decision-Making Process for Clinical Trial Volunteers: Using Data to Shape Better Experiences
- T-19: Role of Social Media in Patient-Reported Outcomes (PRO) Research
- T-21: Measuring the Impact of CISCRP’s AWARE for All program on Clinical Research Literacy in the US
- T-22: Current Genetics Literacy, Perspectives, and Experiences of Cancer, Chronic, and Rare Disease Patients and Caregivers
- T-23: New Methodology to Evaluate a Drugs Effect on Respiratory Depression
- T-24: A Phase 1 pilot trial to explore safety, pharmacokinetics, and bioavailability of intranasal remimazolam in healthy subjects
- T-25: Understanding the Human Challenges Facing Oncologist who Treat NSCLC
- T-26: Prior Assessment Consultation for Cell Therapy Products to Enhance the Investigational New Drug Application Quality in Chines Taipei
- T-27: MADDERS: A Systematic Approach to Meeting Regulatory Requirements for Evaluating Abuse-Related Events in Clinical Trials
- T-28: Assessment of the Quality Decision-Making Practices; Case Studies with a Pharmaceutical Company, Regulatory and HTA Agency
- T-29: Implementing Distinguishable Suffixes for Biologics: Considerations for Application to Previously Licensed Products
- T-30: The Evolution of Privacy Protections in the US and EU
- T-31: Regulatory and Clinical Perspectives on Non-Comparable Biologics
- T-32: CMC Outsourcing Through Contract Manufacturing Organization (CMO): Opportunities, Risks and Mitigation
- T-33: Assessing the Implementation of Value-Based Payments for Oncology Treatment Within the Existing Care Structure
- W-01: Comparison of Predictive Power of ECG Biomarkers for Detection of Drug-Induced Cardiac Ion Channel Block
- W-02: Regulatory Implications for the Safety of CAR-T Gene Therapy
- W-03: Full Scale Implementation of Medical Information Database Network (MID-NET®) of 23 Hospitals for Drug Safety Assessment.
- W-04: Understanding Safety Reporting Requirements: Perspectives from Asia, US and Europe
- W-05: QPPV, CO, and None: Which is Working and Which is Not Working?
- W-06: Challenges, Outcomes and Benefits of Leveraging eSource Solution in Clinical Trials
- W-07: Aligning Strategies and Deliverables for Global eCOA Translation Submissions to Ethics Committees in Clinical Trials
- W-08: Taming the Study Data Explosion: How to Leverage KPIs to Maximize Performance
- W-09: Data Quality in a Longitudinal, Observational Registry Without On-site Monitoring: Findings From the ORBIT AF II Registry
- W-10: How Evaluating Human Emotions Could Provide Valuable Evidence to Support Clinical Trial Endpoints
- W-11: Innovations in the Management of Study Drug Inventory Through a Web-Based System
- W-12: The Clinical Development Design (CDD) Framework: Assisting and Improving Decision-Making for Product Development
- W-13: Comparing Two Drug Treatment Coding Approaches: Coding Challenges and Lessons Learned
- W-14: SDTM and CDASH: Why You Need Both
- W-15: Cross-Industry Collaboration Evaluating how Blockchain can Transform the Pharmaceutical and Healthcare Industry
- W-16: The Cost Effectiveness of Metastatic Melanoma Treatment in Taiwan
- W-17: A Digital Health Platform to Create Personalized Care Experiences for Patients with Chronic Disease
- W-18: Monitoring and Evaluating Community Stakeholder Engagement Strategies in Populations at High Risk of HIV in Pattaya, Thailand
- W-19: Gene Therapy Clinical Trials in Rare Diseases: Considerations and Tools for Observing Delayed Adverse Events
- W-20: Designing a Patient-Centric Web-Based Registry
- W-21: Effective Engagement Between Sponsors & Patient Groups: A Structured Process and Use Cases from CTTI
- W-22: Leveraging Physician Referral Networks in Rare Disease Genotyping
- W-23: Participation Barometer: Learn What Influences Patient Decision-Making
- W-24: Where High Touch Meets High Tech: Reimagining Innovation In Clinical Trials
- W-25: The Use of Voice Assistant Technology to Increase Engagement in Clinical Trials
- W-26: A Novel Eyedrop to Treat Myopia
- W-27: Placebo Response Reduction Training in Chronic Low Back Pain: Comparison to Other Published Studies on Chronic Low Back Pain
- W-28: Visualizing Clinical Trial Endpoints
- W-29: Analysis of Pediatric Investigation Plans and Post-Approval Pediatric Requirements of Monoclonal Antibodies for Asthma
- W-31: An Adaptive Seamless Phase II/III Design in Drug Development for Binary Endpoints
- W-32: Analysis of Prescription Drug Direct-to-Consumer (DTC) Television Commercials Released Between 2000-2017
- W-33: Evaluation Process for Bulk Drug Substances for use in Pharmacy Compounding at the FDA: Weighing in the Nonclinical Assessment
- W-34: Effect of Randomization Schemes in the Master Protocol Framework When There Are Unknown Interactions Between Biomarkers